AGMB Stock Forecast & Price Target

AgomAb Therapeutics is attractive fundamentally because ontunisertib has already shown a rare combination of clean safety, confirmed GI restriction, and objective anti-fibrotic activity in a disease with no approved pharmacologic therapy, including 31.8% conversion of non-passable strictures to passable at 200 mg BID and balanced adverse events versus placebo in 103 FSCD patients. Its platform thesis is strengthened by the same organ-restriction logic extending to AGMB-447, which has demonstrated low systemic exposure, strong lung target engagement, and no systemic safety signal in 108 healthy participants, creating two shots on goal against a highly validated but historically toxicity-limited ALK5 target. The outlook is further supported by a pro forma cash position of approximately €275M and runway into 1H29E, which should fund the key 2H26 catalysts while the stock still appears to trade at a roughly 14-16x discount to comparable peers.

AgomAb Therapeutics is viewed negatively because it remains a clinical-stage company with no approved drugs, and both ontunisertib and AGMB-447 are still early enough that clinical success may not translate into approval. Regulatory risk is elevated because endpoints can change and even positive data may not secure U.S. or ex-U.S. approval, while reliance on external CMOs adds execution risk that could delay development. Financially, approximately €285M in pro forma cash may still be insufficient to fund continued clinical and preclinical work, implying the need for additional capital that could dilute shareholders, especially if either ALK5/TGFβR1 program shows safety or efficacy weakness.